Heyholder
‹ Activism Filings

SAMJIN PHARMACEUTICAL CO.,LTD Q3 operating profit KRW 11.9 billion, up 22.0% from a year earlier

SAMJIN PHARMACEUTICAL CO.,LTD· Periodic Report

AI summary · Not investment advice

Samjin Pharmaceutical sold KRW 84.1 billion in Q3 and made KRW 11.9 billion from its main business, up 22.0% from a year earlier and up 66.8% from the previous quarter.

Operating profit · 3 months

KRW 11.9 billion

Key facts

Revenue (3 months)
KRW 84.1 billion
Net income (3 months)
KRW 8.2 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 83.1 billion
Revenue (year to date)
KRW 231.8 billion
Operating profit (prior-year 3 months)
KRW 9.8 billion
Operating profit (year to date)
KRW 22.7 billion
Net income (prior-year 3 months)
KRW 6.8 billion
Net income (year to date)
KRW 15.7 billion

Commentary

AI commentary · Not investment advice

What happened

Samjin Pharmaceutical filed its quarterly report for the third quarter of 2026, on a standalone basis. Sales for the 3 months were KRW 84.07 billion, up 1.1% from the same period a year earlier. They rose 5.6% from the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was KRW 11.93 billion. That is up 22.0% from a year earlier and up 66.8% from the previous quarter. Net income (final profit after taxes and all other costs) for the 3 months was KRW 8.16 billion. That is up 19.3% from a year earlier and up 33.8% from the previous quarter.

What changes for shareholders

For the year to date, sales were KRW 231.78 billion. Operating profit was KRW 22.67 billion. Net income was KRW 15.65 billion.

Comments

No comments yet

Comments from shareholders will appear here.